| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.26 | 3e-06 |
| mRNA | SB-225002 | CTRPv2 | pan-cancer | AAC | 0.16 | 4e-06 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.16 | 4e-06 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.18 | 1e-05 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.24 | 1e-05 |
| mRNA | rigosertib | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-05 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | 0.17 | 3e-05 |
| mRNA | IOX2 | GDSC1000 | pan-cancer | AAC | -0.16 | 5e-05 |
| mRNA | SN-38 | GDSC1000 | pan-cancer | AAC | 0.16 | 7e-05 |
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | 0.14 | 9e-05 |